[go: up one dir, main page]

UY28423A1 - Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- - Google Patents

Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-

Info

Publication number
UY28423A1
UY28423A1 UY28423A UY28423A UY28423A1 UY 28423 A1 UY28423 A1 UY 28423A1 UY 28423 A UY28423 A UY 28423A UY 28423 A UY28423 A UY 28423A UY 28423 A1 UY28423 A1 UY 28423A1
Authority
UY
Uruguay
Prior art keywords
ns4a
compounds
hcv
relates
proteasa
Prior art date
Application number
UY28423A
Other languages
English (en)
Inventor
Shawn D Britt
Kevin M Cottrell
Robert B Perni
Pitlik Janos
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of UY28423A1 publication Critical patent/UY28423A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invneción se relaciona con los compuestos de la fórmula I o de fórmula Ia o sales de las mismas farmacéuticamente aceptables, que inhiben la actividad de proteasa de serina, particularmente la actividad del virus de hepatitis C de la proteasa NS3- NS4A. Como tal, actúan interfiriendo con el ciclo de vida del virus de la hepatitis C y son útiles como agentes antivirales. La invneicón se relaciona además con composiciones farmacéuticamente aceptables que comprenden dichos compuestos ya sean por utilización ex vivo o por suministro a un paciente que sufre de infección de HCV y procesa la preparación de los compuestos. La invención se relaciona también con los métodos para tratar una infección de HCV en un paciente suministrando una composición farmacológica que comprende un compuesto de esta invención.
UY28423A 2003-07-18 2004-07-16 Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- UY28423A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48853503P 2003-07-18 2003-07-18

Publications (1)

Publication Number Publication Date
UY28423A1 true UY28423A1 (es) 2005-02-28

Family

ID=34079432

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28423A UY28423A1 (es) 2003-07-18 2004-07-16 Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-

Country Status (18)

Country Link
US (2) US7109172B2 (es)
EP (3) EP2341065A3 (es)
JP (2) JP4745230B2 (es)
KR (2) KR20060052836A (es)
CN (3) CN1852920B (es)
AR (1) AR045916A1 (es)
AU (2) AU2004257288A1 (es)
BR (1) BRPI0412761A (es)
CA (1) CA2532664A1 (es)
IL (2) IL173180A0 (es)
NO (1) NO20060706L (es)
NZ (1) NZ544789A (es)
PE (1) PE20050251A1 (es)
RU (1) RU2412198C2 (es)
TW (1) TW200523270A (es)
UY (1) UY28423A1 (es)
WO (1) WO2005007681A2 (es)
ZA (1) ZA200601420B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) * 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
ATE297946T1 (de) * 2000-04-03 2005-07-15 Vertex Pharma Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CA2481369C (en) * 2002-04-11 2012-07-10 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN1852920B (zh) * 2003-07-18 2010-12-15 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
TWI359147B (en) * 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
AU2004274468B2 (en) 2003-09-18 2009-07-23 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MXPA06004006A (es) * 2003-10-10 2006-06-28 Vertex Pharma Inhibidores de serina proteasas, especialmente de ns3-ns4a proteasa del virus de la hepatitis c.
BRPI0415935A (pt) * 2003-10-27 2007-01-02 Vertex Pharma combinações para tratamento de hcv
JP2008505849A (ja) * 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
EP2546246A3 (en) 2005-05-13 2013-04-24 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
ES2572980T3 (es) * 2005-06-02 2016-06-03 Merck Sharp & Dohme Corp. Combinación de inhibidores de la proteasa del VHC con un tensioactivo
US20070105781A1 (en) * 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2629343A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
WO2007133865A2 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors an their uses
EP2374812B1 (en) 2006-07-13 2015-04-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008057995A2 (en) * 2006-11-02 2008-05-15 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
EA201101492A1 (ru) 2006-11-15 2012-09-28 Вирокем Фарма Инк. Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
CA2679312A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP5723783B2 (ja) 2008-12-10 2015-05-27 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製の阻害剤としての新しい４−アミノ−４−オキソブタノイルペプチド
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
PL2477980T3 (pl) 2009-09-15 2017-02-28 Taigen Biotechnology Co., Ltd. Inhibitory proteazy hcv
MX2012006026A (es) 2009-11-25 2012-08-15 Vertex Pharma Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
US20130072523A1 (en) 2009-12-24 2013-03-21 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
CN103038237A (zh) 2010-03-24 2013-04-10 沃泰克斯药物股份有限公司 用于黄病毒感染治疗或预防的类似物
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
JP2013529684A (ja) 2010-06-28 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
JP2013534249A (ja) 2010-08-17 2013-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス科ウイルス感染の処置または予防のための化合物および方法
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
TW201317223A (zh) 2011-07-26 2013-05-01 Vertex Pharma 噻吩化合物
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
US9115175B2 (en) 2013-03-14 2015-08-25 Achillion Pharmaceuticals, Inc. Processes for Producing sovaprevir
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
AU2014227849A1 (en) 2013-03-15 2015-10-01 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
NZ769391A (en) * 2014-10-27 2024-12-20 Sanofi Aatd Inc Serpin fusion polypeptides and methods of use thereof
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
MX392422B (es) 2016-06-21 2025-03-24 Orion Ophthalmology LLC Derivados de prolinamida heterociclica
US20220099637A1 (en) 2018-12-04 2022-03-31 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
ATE244717T1 (de) 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
JP4690545B2 (ja) * 1998-03-31 2011-06-01 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
EP1964561A1 (en) 1999-03-19 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ATE297946T1 (de) * 2000-04-03 2005-07-15 Vertex Pharma Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
CN1498224A (zh) * 2000-07-21 2004-05-19 ���鹫˾ 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP4455056B2 (ja) 2001-07-11 2010-04-21 バーテックス ファーマシューティカルズ インコーポレイテッド 架橋二環式セリンプロテアーゼ阻害剤
ATE539744T1 (de) * 2001-10-24 2012-01-15 Vertex Pharma Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
CA2481369C (en) * 2002-04-11 2012-07-10 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
JP2005537861A (ja) 2002-09-04 2005-12-15 クオンタム ディヴァイスィズ，インコーポレイテッド 筋肉又は関節の痛みの処置のための電気光学装置及び方法
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ATE547412T1 (de) * 2003-04-11 2012-03-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
CN1852920B (zh) * 2003-07-18 2010-12-15 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
TWI359147B (en) * 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
AU2004274468B2 (en) 2003-09-18 2009-07-23 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MXPA06004006A (es) * 2003-10-10 2006-06-28 Vertex Pharma Inhibidores de serina proteasas, especialmente de ns3-ns4a proteasa del virus de la hepatitis c.
JP2008505849A (ja) 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂

Also Published As

Publication number Publication date
EP2341065A3 (en) 2012-06-20
IL218698A0 (en) 2012-05-31
JP4745230B2 (ja) 2011-08-10
AU2010257200B2 (en) 2011-10-20
EP2368900A3 (en) 2012-07-04
WO2005007681A2 (en) 2005-01-27
KR20060052836A (ko) 2006-05-19
KR20120013450A (ko) 2012-02-14
PE20050251A1 (es) 2005-04-13
CA2532664A1 (en) 2005-01-27
CN101724022A (zh) 2010-06-09
NZ544789A (en) 2010-01-29
EP2368900A2 (en) 2011-09-28
JP2011116784A (ja) 2011-06-16
US7109172B2 (en) 2006-09-19
CN1852920A (zh) 2006-10-25
US8691758B2 (en) 2014-04-08
AU2004257288A1 (en) 2005-01-27
EP1646642A2 (en) 2006-04-19
TW200523270A (en) 2005-07-16
NO20060706L (no) 2006-02-14
ZA200601420B (en) 2007-06-27
US20050107304A1 (en) 2005-05-19
US20060211629A1 (en) 2006-09-21
HK1098164A1 (en) 2007-07-13
AR045916A1 (es) 2005-11-16
RU2412198C2 (ru) 2011-02-20
CN1852920B (zh) 2010-12-15
JP2008500265A (ja) 2008-01-10
CN102020700A (zh) 2011-04-20
EP2341065A2 (en) 2011-07-06
AU2010257200A1 (en) 2011-01-13
BRPI0412761A (pt) 2006-09-26
RU2006105002A (ru) 2006-08-27
AU2004257288A2 (en) 2008-06-26
IL173180A0 (en) 2006-06-11
WO2005007681A3 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
UY28500A1 (es) Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
UY30527A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
CL2008003384A1 (es) Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
MX2009009176A (es) Inhibidores de serina-proteasas.
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE447573T1 (de) Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer
BRPI0410456A (pt) compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PA8683801A1 (es) Derivados de quinolina como agentes antibacterianos